---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-24-000067"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:40:06.924239+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio Phase 2B trial of ANB032 fails endpoints in atopic dermatitis; cash ~$415M

## Summary
- ANB032 did not meet primary endpoint EASI-75 or any secondary endpoints at Week 14 in 201-patient ARISE-AD trial.
- Higher placebo rates than historical norms, particularly in U.S., contributed to failure; drug well tolerated with no safety signals.
- Cash, equivalents and investments expected to be ~$415M at Dec 31, 2024, funding operations through year-end 2027.
- One serious adverse event (worsening AD) across active arms; no dose relationship or imbalance in adverse events.

## SEC filing metadata
- accession: 0001370053-24-000067
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000067/0001370053-24-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000067/anab-20241211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-24-000067
- JSON: https://secwatch.observer/filing/0001370053-24-000067.json
- Plain text: https://secwatch.observer/filing/0001370053-24-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.